Pharmacology, toxicity, and therapeutic usefulness of amphotericin B.

The polyene antibiotic, amphotericin B, has been used clinically for nearly ten years, and during this time, it has played a paramount role in the treatment of systemic fungal diseases. Recently reported studies not only have confirmed the early favorable reports but have served to define more clearly the degree of effectiveness of the drug in treatment of specific fungal infections. In addition, certain aspects of the pharmacological and toxic properties of the drug have been explained. Drug Preparations Amphotericin B is available in two types of preparations, one which forms a microcrystalline suspension and the other which forms a colloidal suspension in water. Microcrystalline Preparation.— This material is marketed in two forms. The first is for topical application and includes 3% amphotericin B in appropriate vehicles to form a lotion, cream, or ointment. It has been used for topical application in superficial Candida infections. 1 The second, or oral

[1]  A. Leaf,et al.  EFFECT OF AMPHOTERICIN B ON THE PERMEABILITY OF THE TOAD BLADDER. , 1965, The Journal of clinical investigation.

[2]  D. Alling,et al.  Potassium Loss from Human Erythrocytes Exposed to Amphotericin B , 1965, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[3]  H. Blank,et al.  Fungus Diseases and Their Treatment , 1965 .

[4]  J. A. McChesney,et al.  HYPOKALEMIC PARALYSIS INDUCED BY AMPHOTERICIN B. , 1964, JAMA.

[5]  F. Stohlman,et al.  ANEMIA INDUCED BY AMPHOTERICIN B. , 1964, JAMA.

[6]  J. Bennett,et al.  Amphotericin B Toxicity: Combined Clinical Staff Conference at the National Institutes of Health , 1964 .

[7]  D. Alling,et al.  NEPHROTOXICITY OF AMPHOTERICIN B; EARLY AND LATE EFFECTS IN 81 PATIENTS. , 1964, Annals of internal medicine.

[8]  W. Winn.  THE TREATMENT OF COCCIDIOIDAL MENINGITIS. THE USE OF AMPHOTERICIN B IN A GROUP OF 25 PATIENTS. , 1964, California medicine.

[9]  J. Bennett,et al.  Electrocardiographic and Electrolyte Abnormalities Caused by Amphotericin B in Dog and Man , 1964, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[10]  J. Seabury,et al.  RESULTS OF THE TREATMENT OF SYSTEMIC MYCOSES. , 1964, JAMA.

[11]  V. P. Cirillo,et al.  ACTION OF THE POLYENE ANTIBIOTICS FILIPIN, NYSTATIN AND N-ACETYLCANDIDIN ON THE YEAST CELL MEMBRANE. , 1964, Journal of general microbiology.

[12]  W. Butler,et al.  INTRAVENOUS ADMINISTRATION OF AMPHOTERICIN B IN THE DOG. , 1964, Journal of the American Veterinary Medical Association.

[13]  J. Bennett,et al.  DETECTION OF CRYPTOCOCCAL POLYSACCHARIDE IN SERUM AND SPINAL FLUID: VALUE IN DIAGNOSIS AND PROGNOSIS. , 1964, Transactions of the Association of American Physicians.

[14]  W. Butler,et al.  AMPHOTERICIN B RENAL TOXICITY IN THE DOG. , 1964, The Journal of pharmacology and experimental therapeutics.

[15]  J. J. Ghosh,et al.  ABSORPTION OF AMPHOTERICIN B BY CANDIDA ALBICANS. , 1963, Annals of biochemistry and experimental medicine.

[16]  A. Ommaya.  Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid. , 1963, Lancet.

[17]  W. Butler,et al.  Lethal Toxicity and Dose-Related Azotemia Due to Amphotericin B in Dogs , 1963, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[18]  W. A. Winn.  COCCIDIOIDOMYCOSIS AND AMPHOTERICIN B. , 1963, The Medical clinics of North America.

[19]  M. Furcolow.  THE USE OF AMPHOTERICIN B IN BLASTOMYCOSIS, CRYPTOCOCCOSIS AND HISTOPLASMOSIS. , 1963, The Medical clinics of North America.

[20]  J. Utz.  SYSTEMIC FUNGAL INFECTIONS AMENABLE TO CHEMOTHERAPY , 1963, Disease-a-month : DM.

[21]  M. Kress,et al.  PULMONARY AND MENINGEAL CRYPTOCOCCOSIS: SUCCESSFUL TREATMENT OF THE MENINGITIS WITH LATERAL CEREBRAL INTRAVENTRICULAR INJECTION OF AMPHOTERICIN B. , 1963, Archives of internal medicine.

[22]  D. Alling,et al.  Reducing amphotericin B reactions. A double-blind study. , 1963, The American review of respiratory disease.

[23]  J. Utz,et al.  The improved prognosis of cryptococcal meningitis with amphotericin B therapy. , 1962, Annals of internal medicine.

[24]  M. Furcolow.  Comparison of treated and untreated severe histoplasmosis. , 1963 .

[25]  S. Kinsky.  MEMBRANE STEROLS AND THE SELECTIVE TOXICITY OF POLYENE ANTIFUNGAL ANTIBIOTICS. , 1963, Antimicrobial agents and chemotherapy.

[26]  J. Bennett,et al.  CORRELATION OF PARTICLE SIZE OF INTRAVENOUS AMPHOTERICIN B WITH TOXIC AND CHEMOTHERAPEUTIC EFFECTS. , 1963, Antimicrobial agents and chemotherapy.

[27]  S. Olansky,et al.  Topical treatment of cutaneous moniliasis with an amphotericin B lotion. , 1962, Antibiotics & chemotherapy.

[28]  J. J. Procknow.  Treatment of opportunistic fungus infections. , 1962, Laboratory investigation; a journal of technical methods and pathology.

[29]  W. Lockwood,et al.  Experiences in the treatment of North American blastomycosis with 2-hydroxystilbamidine. , 1962, Annals of internal medicine.

[30]  N. Bell,et al.  On the nephrotoxicity of amphotericin B in man. , 1962, The American journal of medicine.

[31]  H. Kravetz,et al.  The use of amphotericin B in man. , 1962, JAMA.

[32]  E. Borowski,et al.  Water-soluble N-acetyl derivatives of heptaene macrolide antifungal antibiotics: microbiological studies. , 1961, Antibiotics & chemotherapy.

[33]  E. Fonkalsrud,et al.  Experimental studies and clinical experience with isolated limb perfusion of fungicidal drugs. , 1961, Surgery, gynecology & obstetrics.

[34]  H. Kravetz,et al.  Oral administration of solubilized amphotericin B. , 1961, The New England journal of medicine.

[35]  J. Lampen,et al.  The effect of monovalent cations on the inhibition of yeast metabolism by nystatin. , 1961, Journal of general microbiology.

[36]  J. Seabury.  Experience with amphotericin B. , 1961, Chemotherapia.

[37]  J. Seabury,et al.  EXPERIENCE WITH AMPHOTERICIN B , 1960, Annals of the New York Academy of Sciences.

[38]  L. Friedman,et al.  Chromoblastomycosis treated by vibrapuncture injection of amphotericin B. , 1959, Archives of dermatology.

[39]  K. Kilburn.  The innocuousness and possible therapeutic use of aerosol amphotericin-B. , 1959, The American review of respiratory disease.

[40]  Cerruti Mm,et al.  Intrathoracic injection of amphotericin B in the treatment of monilial empyema. , 1959 .

[41]  Louria Db.  Some aspects of the absorption, distribution, and excretion of amphotericin B in man. , 1958 .

[42]  M. Littman,et al.  Coccidioidomycosis and its treatment with amphotericin B. , 1958, American Journal of Medicine.

[43]  M. Lepper,et al.  Use of amphotericin to eliminate Candida from the stools of infants treated with tetracycline. , 1958, Antibiotics annual.

[44]  E. Bartner,et al.  Studies on a new solubilized preparation of amphotericin B. , 1957, Antibiotics annual.